Aralez Pharmaceuticals' YOSPRALA -- a once-a-day medication that combines aspirin, an anti-platelet agent and omeprazole into a proton pump inhibitor (PPI) -- is now available in the United States. Read More »

TRACON Pharmaceuticals has completed its “End-of-Phase 2” meeting with the U.S. Food and Drug Administration and its “Protocol Assistance Meeting” with the European Medicines Agency. Read More »

Eisai Inc. and Arena Pharmaceuticals have released BELVIQ XR, a medication designed to help individuals lose weight and maintain their weight loss. Read More »

Braeburn Pharmaceuticals and Camurus have enrolled the first Phase 3 CAM2038 trial patients to assess the safety and effectiveness of CAM2038 in patients with lower back pain whose present course of treatment involves opioids. Read More »

Regeneron Pharmaceutical's Phase 2 CAPELLA trial has turned in positive results. Read More »

AbbVie's investigational, pan-genotype regimen of gelcaprevir (ABT-493) and pibrentasvir (ABT-530) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »

Teva Pharmaceutical Industries has launched Abacavir and Iamivudine tablets, the company’s generic version of Epzicom tablets, in the United States. Read More »

Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »

Bayer and DelSiTech have issued a joint announcement regarding the signing of a Collaboration and Technology License Agreement. Read More »

Eleventa, a portfolio company owned by Maxwell Biotech Venture Fund in association with its development partner Oxagen Ltd., has finalized patient enrollment for its Phase 3 Timapiprant clinical trial. Read More »

The U.S. Food and Drug Administration has given its approval of the MiniMed 670G hybrid closed looped system, designed to automatically monitor glucose and give suitable dose to individuals 14 years of age and older. Read More »

The U.S. Food and Drug Administration, under a Special Protocol Assessment, has agreed to Athersys' design and analysis of a Multistem Phase 3 study. Read More »

AcelRx Pharmaceuticals has commenced with its IAP312 Phase 3 trial for the study of Zalviso, its new investigational product in development to treat moderate-to-severe acute pain in adult hospital patients. Read More »

Corvus Pharmaceuticals has released the preclinical data and preclinical biomarker data from its Phase 1/1b CPI-444 clinical study. Read More »

H. Lundbeck and Otsuka Pharmaceutical Development & Commercialization have reported that the U.S. Food and Drug Administration has approved the update to the Rexulti label. Read More »

Ajanta Pharma USA has made Omeprazole and Sodium Bicarbonate Powder for Oral Suspension available in the United States. Read More »

The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »

Mucodel Pharma, a private company based in Greensboro, North Carolina, that is dedicated to the development of improved rescue therapies to be administered oromucosally, has completed its Exonal (buccal naloxone) clinical study. Read More »

Pacira Pharmaceuticals has released new data supporting EXPAREL and the benefits it could offer patients who must undergo third molar, or wisdom teeth, removal. Read More »

Epizyme Inc. has agreed to a partnership with Foundation Medicine to identify and enroll support patients for the upcoming Phase 2 trial of tazemetostat on patients who have non-Hodgkin lymphoma. Read More »